Hyperpharm Limited Pharmaceutical Import Profile — Mauritius (DGFT 2022–2026)

Name: Hyperpharm Limited Pharmaceutical Import Records from India — 2 Products, $180.1K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hyperpharm Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $180.1K Trade | TransData Nexus

Hyperpharm Limited

Pharmaceutical Importer · Mauritius · Advanced Oncology Focus · $180.1K Total Trade · DGFT Verified

Hyperpharm Limited is a pharmaceutical importer based in Mauritius with a total trade value of $180.1K across 2 products in 2 therapeutic categories. Based on 52 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Hyperpharm Limited sources from 21 verified Indian suppliers, with Indus Life Sciences Private Limited accounting for 22.6% of imports.

Hyperpharm Limited — Import Portfolio & Supplier Network

Hyperpharm Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Hyperpharm Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Indus Life Sciences Private Limited	$278.3K	47	22.6%
Citro Pharma Private Limited	$172.9K	224	14.1%
Dr Reddys Laboratories Limited	$118.6K	9

What Formulations Does Hyperpharm Limited Import?

Formulation	Value	Ships
Gripex plus sachets paracetamol 500 MG	$66.1K	2
Harmless medicines - glipmevia 50/1000 tablet 3x10's packing	$50.0K	1
Gripex plus sachets paracetamol 500mgphenylephrine hcl BP 10 MG cetrizine hydrochloride BP 2.5MG and vitamin c BP	$33.1K	1
Mucoril chesty cough syrup 200ML	$30.0K	2
Dexfine dry cough syrup 200ML	$30.0K	2
Harmless medicines for human consumption- furosemide 40MG	$25.1K	1
Flutex - p nasal spray 120 md	$23.5K	1
Dexfine dry cough syrup 200ML free samples -700	$23.2K	1
Mucoril chesty cough syrup 200ML free samples -700	$23.2K	1
Reclide 80MG TAB 20s batch	$22.2K	1
Pharma product : nexipox varicella vaccine live i.p. quentity: 769.00 nos +231 nos free	$21.9K	1
Hervycta INJ 150mgtrastuzumab 150MG	$20.2K	1
Pharma.ingredient of ind.originpharma.finished formulation for pharma.industry-dapafloz-10/1000 dapagliflozin	$20.1K	1
Natural cough & flu herbal granules 8 sachet	$19.8K	2
Pharma.ingredient of ind.originpharma.finished formulation for pharma.industry-lina nish 2.5/1000 linagliptin 2.5MG	$19.7K	1

Hyperpharm Limited imports 489 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Rituximab	Advanced Oncology	$156.9K	6	0.8%	14
2	Instrument	Medical Devices & Diagnostics	$23.2K	46	1.7%	9

Hyperpharm Limited imports 2 pharmaceutical products across 2 categories into Mauritius totaling $180.1K.

Hyperpharm Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Hyperpharm Limited, established in 2011 and operational since 2013, has rapidly ascended to prominence as one of Mauritius's fastest-growing pharmaceutical wholesalers. Headquartered in Saint-Pierre, the company has expanded its footprint to include a chain of 12 retail pharmacies, collectively holding over 10% of the retail pharmacy market share in Mauritius. (hyperpharm.mu) This growth underscores Hyperpharm's significant role in the nation's pharmaceutical distribution landscape.

The company's diverse operations encompass the importation, wholesaling, distribution, and promotion of pharmaceutical products, medical consumables, and consumer goods. Hyperpharm's mission is to redefine healthcare solutions, aiming to be among the top five wholesalers in its segment by 2025. (hyperpharm.mu) This strategic vision reflects a commitment to enhancing healthcare accessibility and quality in Mauritius.

2Distribution Network

Hyperpharm Limited's distribution network is robust and expansive, featuring a central warehouse located at Morcellement Traffic Centre in Saint-Pierre. (hyperpharm.mu) This facility serves as the hub for the company's operations, facilitating efficient logistics and inventory management. The network extends across Mauritius through its 12 retail pharmacies, strategically situated in key urban centers such as Port-Louis, Quatre Bornes, Curepipe, and Saint-Pierre. This widespread presence ensures comprehensive coverage of the island, enabling Hyperpharm to effectively meet the pharmaceutical needs of both urban and rural populations.

While the company's primary focus is on the Mauritian market, Hyperpharm has also ventured into regional markets, including Madagascar and Seychelles. This expansion indicates a strategic intent to leverage its distribution capabilities beyond national borders, tapping into the broader Indian Ocean region. (hyperpharm.mu)

3Industry Role

In Mauritius's pharmaceutical supply chain, Hyperpharm Limited functions as a multifaceted entity, operating as a wholesaler, importer, distributor, and promoter. The company imports a diverse range of pharmaceutical products, including finished formulations such as tablets, capsules, syrups, and injections, primarily sourced from India. This extensive import portfolio underscores Hyperpharm's pivotal role in ensuring the availability of essential medications across the island.

Additionally, Hyperpharm's ownership and operation of 12 retail pharmacies position it as a significant player in the retail sector. These pharmacies not only serve as direct points of sale but also act as critical distribution channels, enhancing the company's reach and influence within the pharmaceutical market. This dual role in both wholesale and retail segments enables Hyperpharm to maintain a comprehensive presence in the Mauritian pharmaceutical landscape.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Hyperpharm Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Hyperpharm Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. The company's total import value from India stands at $180,000 USD, encompassing 52 shipments across two therapeutic categories. This concentration is further highlighted by the dominance of two primary products: Rituximab, accounting for $157,000 USD (87.1% of the total import value), and an unspecified instrument valued at $23,000 USD (12.9% of the total import value).

The reliance on a limited number of products and suppliers suggests a strategic focus on high-demand, specialized items. However, this concentration also introduces potential risks, such as supply chain disruptions or price volatility. The stability of Hyperpharm's relationships with its Indian suppliers is crucial to mitigate these risks. The company's extensive engagement with multiple Indian suppliers, as evidenced by 52 shipments from 21 unique suppliers, indicates a diversified sourcing approach within the Indian market. This diversification may help in reducing dependency on a single supplier, thereby enhancing supply chain resilience.

2Supply Chain Resilience

Hyperpharm Limited's supply chain resilience is influenced by its sourcing practices and the diversity of its supplier base. The company's engagement with 21 unique Indian suppliers for 52 shipments suggests a level of diversification that can mitigate risks associated with over-reliance on a single supplier. This strategy may provide flexibility in addressing potential supply chain disruptions.

Importing Pharmaceuticals into Mauritius — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Mauritius

1Regulatory Authority & Framework

In Mauritius, the regulation of pharmaceutical products is overseen by the Pharmacy Board, operating under the Ministry of Health and Wellness. The Pharmacy Act governs the importation, registration, and distribution of pharmaceutical products, ensuring that all medications meet the required standards of quality, safety, and efficacy.

The Act stipulates that no pharmaceutical product shall be imported unless it is registered with the Board. Applicants seeking registration must submit an application accompanied by a non-refundable processing fee. Upon receipt, the Board refers the application to the Trade and Therapeutics Committee for recommendations. This process ensures that only products meeting the established criteria are permitted for importation and distribution within Mauritius.

2Import Licensing & GMP

Import licensing for pharmaceutical products in Mauritius is governed by the Pharmacy Act, which requires importers to obtain clearance from the Registrar before importing any pharmaceutical product. This clearance process involves submitting a pro forma invoice and other relevant documents through the TradeNet system. The Registrar reviews the application and, upon approval, grants clearance for the removal of the imported products.

Regarding Good Manufacturing Practice (GMP) certifications, Mauritius recognizes standards such as EU GMP, WHO GMP, and PIC/S. Pharmaceutical products imported into Mauritius must comply with these recognized GMP standards to ensure quality and safety. Importers are required to verify that their suppliers hold valid GMP certifications from recognized authorities, ensuring that the products meet international quality standards.

Hyperpharm Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Hyperpharm Limited's product strategy focuses on high-demand therapeutic areas, particularly in advanced oncology and medical devices and diagnostics. The company's import portfolio is heavily weighted towards Rituximab, a critical medication in oncology, indicating a strategic emphasis on providing essential cancer treatments. This focus aligns with the growing demand for specialized healthcare solutions in Mauritius.

The decision to import a significant volume of Rituximab suggests a strategic alignment with market needs and a commitment to addressing critical health challenges. By concentrating on these therapeutic areas, Hyperpharm aims to position itself as a key provider of specialized medical solutions, catering to the evolving healthcare demands of the Mauritian population.

2Sourcing Profile

Hyperpharm Limited's sourcing strategy is

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Hyperpharm Limited

What products does Hyperpharm Limited import from India?

Hyperpharm Limited imports 2 pharmaceutical products across 2 categories. Top imports: Rituximab ($156.9K), Instrument ($23.2K).

Who supplies pharmaceuticals to Hyperpharm Limited from India?

Hyperpharm Limited sources from 21 verified Indian suppliers. The primary supplier is Indus Life Sciences Private Limited (22.6% of imports, $278.3K).

What is Hyperpharm Limited's total pharmaceutical import value?

Hyperpharm Limited's total pharmaceutical import value from India is $180.1K, based on 52 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Hyperpharm Limited focus on?

Hyperpharm Limited imports across 2 categories. The largest: Advanced Oncology (87.1%), Medical Devices & Diagnostics (12.9%).

Get Full Hyperpharm Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.